Akebia Therapeutics, Inc.AKBANASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank85
3Y CAGR-14.3%
5Y CAGR+52.0%
Year-over-Year Change
Price-to-book ratio
3Y CAGR
-14.3%/yr
vs +111.0%/yr prior
5Y CAGR
+52.0%/yr
Recent deceleration
Acceleration
-125.3pp
Decelerating
Percentile
P85
Within normal range
vs 5Y Ago
8.1x
Strong expansion
Streak
1 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 12.70 | +255.8% |
| 2024 | -8.15 | -7.2% |
| 2023 | -7.60 | -137.7% |
| 2022 | 20.17 | +297.9% |
| 2021 | 5.07 | +223.7% |
| 2020 | 1.57 | -17.4% |
| 2019 | 1.90 | +86.5% |
| 2018 | 1.02 | -81.2% |
| 2017 | 5.42 | -6.0% |
| 2016 | 5.76 | - |